Immunophil-ME 50 mg Capsule contains Ciclosporin 50 mg, an immunosuppressive agent primarily used to prevent organ transplant rejection and to treat various autoimmune disorders. Ciclosporin acts by selectively inhibiting the activation of T-lymphocytes, thereby suppressing the immune response. This mechanism is essential in reducing the risk of graft rejection in kidney, liver, and heart transplant recipients. Additionally, Immunophil-ME is indicated in the management of autoimmune conditions such as rheumatoid arthritis, psoriasis, and certain types of nephrotic syndrome. The capsule formulation ensures convenient oral administration with adequate bioavailability. Dosage and duration of treatment should be individualized based on patient condition, therapeutic response, and monitoring of blood Ciclosporin levels to minimize toxicity. Common adverse effects include nephrotoxicity, hypertension, hyperlipidemia, and increased susceptibility to infections. Regular monitoring of renal function, blood pressure, and serum electrolytes is recommended during therapy. Immunophil-ME should be used cautiously in patients with pre-existing renal impairment or uncontrolled hypertension. It is contraindicated in patients with hypersensitivity to Ciclosporin or its components. Concomitant use with nephrotoxic or hepatotoxic drugs requires careful consideration to avoid additive toxicity. Immunophil-ME 50 mg Capsule offers a critical therapeutic option in immunomodulation when used under appropriate medical supervision.